Singular Genomics Systems Inc
NASDAQ:OMIC
Singular Genomics Systems Inc
Cash Equivalents
Singular Genomics Systems Inc
Cash Equivalents Peer Comparison
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
S
|
Singular Genomics Systems Inc
NASDAQ:OMIC
|
Cash Equivalents
$16.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Cash Equivalents
$5.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
38%
|
CAGR 10-Years
14%
|
|
Danaher Corp
NYSE:DHR
|
Cash Equivalents
$7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Cash Equivalents
$70.2m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-5%
|
|
Agilent Technologies Inc
NYSE:A
|
Cash Equivalents
$1.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-4%
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Cash Equivalents
$1.4B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
See Also
What is Singular Genomics Systems Inc's Cash Equivalents?
Cash Equivalents
16.2m
USD
Based on the financial report for Dec 31, 2023, Singular Genomics Systems Inc's Cash Equivalents amounts to 16.2m USD.
What is Singular Genomics Systems Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 3Y
12%
Over the last year, the Cash Equivalents growth was -78%. The average annual Cash Equivalents growth rates for Singular Genomics Systems Inc have been 12% over the past three years .